1. The main problem of smart medical care at present is definitely not the external market, but the management. Hu Ruilian, the current chairman, Ceng Xianwei, the current general manager, and Zeng, the actual controller, all became monks halfway through the acquisition process and entered the CXO industry.
However, this industry has a remarkable feature, and all the people who deal with it are scientists. Therefore, as a counterparty, there must be a top leader with the same level and professional enough to take charge of the overall situation, otherwise it will be difficult to survive in this high-knowledge intensive industry.
1. In the first half of the year, the revenue of the micro-ecological health sector of Ruizhi Pharmaceutical was 654.38+62 million yuan, up by 1 1.04% year-on-year, but the net profit was only 30,649110,000 yuan, down by 14.64% year-on-year. Mainly business restructuring, the micro-ecological nutrition business of the parent company was transferred and invested in Quantum Guangdong, a wholly-owned subsidiary. Quantum Guangdong failed to enjoy relevant tax incentives because it failed to obtain the qualification of high-tech enterprises in the first half of this year. In the same period, the income tax rate of this business segment was adjusted from 15% to 25%, resulting in an increase in tax revenue. In addition, the headquarters and the quantum magnetic industry fund also suffered losses, with a net profit of-21473,800 yuan.
2. At present, the growth rate, net profit and gross profit rate of Wise Medicine are much lower than those of its peers, so it may be necessary to start with the root causes. Wise Chemical, the predecessor of Wise Medicine, was a veteran of CXO industry in China on the same starting line as WuXi PharmaTech. Today, the development of the two cannot be mentioned in the same breath. Smart medicine with a market value of 7 billion is not even a fraction of WuXi Kang Te, and its market value ranks second to last in CXO, which is embarrassing.
3. Ruizhi Chemical was established in April 2003, earlier than the establishment of Tiger Medicine and Kanglong Chemical in 2004. Shang Hua Pharmaceutical, the parent company of Wise Chemical, was listed on NYSE on 20 10, and then delisted on 20 13. The reason for the privatization and delisting of Shang Hua pharmaceutical industry was that China enterprises were generally not recognized in overseas markets at that time. Since its listing, its share price has been fluctuating and falling, from the initial issue price of 65,438+05 USD /ADS to the lowest issue price of 5.92 USD /ADS before privatization. The actual controller believes that delisting is more conducive to its development. WuXi PharmaTech also delisted from the US stock market for the same reason two years later.
4. After several equity transfers on 20 17, Ruizhi Chemical finally acquired 90% equity of Ruizhi Chemical from six counterparties, including Ruiyun Investment, Zhao Rui Investment, CGHK, MegaStar, Zhang Tianxing and Zeng, in May of 20 19, and the transaction price was 2 1.44. The acquisition is also regarded as a backdoor listing of Wise Chemical. After all, the total revenue of Quantum Hi-Tech in 20 17 years is only 275 million yuan, which does not have the strength to acquire Mingzhi Chemical.
5. In the process development and production of biological agents, Ruizhi Pharmaceutical has established a team with rich production experience, which can provide one-stop services covering DNA to IND, including stable cell strain development, process development, preparation research and development, aseptic filling and freeze-drying, drug properties research, packaging material extractables and sediments research, analytical method development, release testing and GMP production.